Ustekinumab biosimilar is under clinical development by DM Bio and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase III drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ustekinumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ustekinumab biosimilar overview
Ustekinumab biosimilar is under development for the treatment of plaque psoriasis, Crohn's disease, psoriatic arthritis and ulcerative colitis. It is administered through subcutaneous route. The drug candidate acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha.
DM Bio overview
DM Bio is a Korean based bio pharmaceutical manufacturing company. The company is also involved in providing various contract manufacturing services ranging from pre-clinical services to sale of in market bio pharmaceutical products.
For a complete picture of Ustekinumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.